Jazz Pharmaceuticals $JAZZ
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS13
PHASE 3 / 2-37
RECRUITING12
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO43%
Delay Index: of 7 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +5.0 months). See all sponsors →
Open Jazz Pharmaceuticals on the live radar map → 📅 $JAZZ readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| HERIZON-GEA-01 NCT05152147 |
P3 | Active, not recruiting | Gastric Neoplasms; Gastroesophageal Adenocarcinoma | 920 | 2026-07-15 (+25 mo) |
| Zanidatamab NCT06695845 |
P2 | Recruiting | Breast Cancer; Gastric Cancer | 200 | 2026-12-31 |
| XYRISE NCT07625280 |
P3 | Recruiting | Narcolepsy; Idiopathic Hypersomnia | 120 | 2027-12-23 |
| EmpowHER 208 NCT07102381 |
P2 | Recruiting | HER2-positive Breast Cancer; Breast Cancer | 125 | 2027-12-29 |
| Lurbinectedin NCT05734066 |
P1/2 | Recruiting | Refractory Ewing Sarcoma; Relapsed Ewing Sarcoma | 60 | 2028-01-28 (+14 mo) |
| Zanidatamab NCT06435429 |
P3 | Recruiting | Metastatic HER2-positive Breast Cancer | 550 | 2028-04-28 (-36 mo) |
| ACTION NCT05580562 |
P3 | Recruiting | H3 K27M; Glioma | 510 | 2028-06 (+22 mo) |
| JZP926 capsule NCT07723963 |
P2/3 | Recruiting | Juvenile Myoclonic Epilepsy | 260 | 2028-08-01 |
| JZP3507 NCT07533942 |
P2 | Recruiting | Meningioma | 30 | 2028-10-25 |
| Zanidatamab NCT06282575 |
P3 | Recruiting | Biliary Tract Cancer | 286 | 2028-12-01 (+5 mo) |
| ONC206 NCT07282587 |
P2 | Recruiting | Advanced Pheochromocytoma and Paraganglioma; PCPG | 90 | 2028-12-15 |
| Lurbinectedin NCT07459634 |
P2 | Recruiting | Extensive-stage Small-cell Lung Cancer | 50 | 2029-08-04 |
| CBD-OS NCT07723976 |
P3 | Recruiting | Developmental and Epileptic Encephalopathy (DEE) | 120 | 2029-09-04 |